Voor zorgverleners

Brainy Briefs

Blijf op de hoogte van de recente MS publicaties

Type 2 inflammatie vormt de basis van comorbiditeit bij atopisch eczeem

Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

The Complex Burden of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes? This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results1

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Publicaties op basis van Nederlandse RWE veiligheids- en effectiviteitsdata in de behandeling van atopisch eczeem

146 for Lipid Management After ACS

Dupixent® CRSwNP